It is anticipated that the FDA is about to approve a third new Alzheimer’s drug, Donanemab. The drug showed a 35% slowdown in cognitive decline in certain patients. To learn more about this drug and who can benefit, read the full article in SciTech Daily, click here.
Gary Skole February 2023 As human beings, socialization is a vital part of our existence. Numerous studies have shown the importance of connecting with others…
Researchers from West Virginia University’s Rockefeller Neuroscience Institute have demonstrated in a proof-of-concept study, published in the New England Journal of Medicine, that focused ultrasound…
Happy New Year! Are you spending any time caring for someone with Alzheimer’s disease, any form of dementia or memory loss? Often, when faced with…
A new study published in the American Journal of Clinical Nutrition suggests that taking a daily multivitamin may help improve memory and slow age-related cognitive…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
Responses